Table 3 GEE models for the impact of clinical factors on the changes in BCVA after treatment.

From: Factors influencing clinical outcomes in patients with diabetic macular edema treated with intravitreal ranibizumab: comparison between responder and non-responder cases

 

All subjects

Responder group

Non-responder group

B (S.E.)

P value

B (S.E.)

P value

B (S.E.)

P value

Age (years)

−0.016 (0.005)

0.001*

−0.002 (0.004)

0.553

−0.008 (0.005)

0.070

HbA1c (%)

−0.056 (0.033)

0.086

−0.060 (0.024)

0.013*

0.019 (0.027)

0.478

Baseline BCVA (LogMAR)

0.520 (0.227)

0.022*

0.657 (0.300)

0.028*

0.250 (0.231)

0.279

Baseline CST (μm)

−0.002 (0.001)

0.063

−0.002 (0.001)

0.019*

−0.002 (0.001)

0.002*

PDR

0.005 (0.097)

0.959

0.083 (0.067)

0.212

−0.143 (0.061)

0.019*

No of IVI

−0.070 (0.033)

0.035*

−0.061 (0.032)

0.053

−0.017 (0.019)

0.389

  1. B (S.E.): regression coefficient (standard error), BCVA: best corrected visual acuity, CST: central subfield thickness, HbA1C: glycosylated hemoglobin, IVI: intravitreal injection, PDR: Proliferative diabetic retinopathy, *P < 0.05.
Back to article page